Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ProKidney ( (PROK) ) has issued an update.
ProKidney Corp. announced that on October 17, 2025, it entered into a new purchase and sale agreement with Northpoint Development, LLC to sell its property in Greensboro, North Carolina for approximately $19.1 million in cash. This transaction, which follows a previously terminated agreement with Williams Development Group, LLC, is part of the company’s strategic efforts to manage its real estate assets effectively.
The most recent analyst rating on (PROK) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
Average Trading Volume: 2,576,740
Technical Sentiment Signal: Buy
Current Market Cap: $894.6M
See more data about PROK stock on TipRanks’ Stock Analysis page.